Estrella Immunopharma, Inc. has completed a registered direct offering that generated approximately $8.0 million in gross proceeds. The offering involved the issuance of 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a single healthcare-focused institutional investor, along with a concurrent private placement of common warrants to purchase up to 7,594,935 additional shares. Aegis Capital Corp. served as the exclusive placement agent for these transactions.
The company plans to use the net proceeds for general corporate purposes and working capital as it advances its CD19 and CD22-targeted ARTEMIS T-cell therapy programs. These funds will specifically support the development of lead candidate EB103, which utilizes Eureka’s ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which employs the same technology to target both CD19 and CD22, another protein commonly found on B-cell malignancies.
This financial milestone comes as Estrella continues its mission to harness the human immune system’s power to transform patient outcomes in cancer and other diseases. The company’s clinical-stage biopharmaceutical focus on T-cell therapies represents a growing area of oncology research that has shown promise in treating various cancers and autoimmune conditions. The additional capital will enable continued progress in these therapeutic areas where significant unmet medical needs persist.
For more information about Estrella Immunopharma’s programs and technology, visit https://www.estrellabio.com/. The original announcement of this funding round can be found at https://ibn.fm/rh6n9. This development follows broader trends in biopharmaceutical financing, where companies developing innovative cell therapies continue to attract investment despite challenging market conditions.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs.